221 related articles for article (PubMed ID: 26398741)
1. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
Johnston W; Essink B; Kirstein J; Forleo-Neto E; Percell S; Han L; Keshavan P; Smolenov I
Pediatr Infect Dis J; 2016 Jan; 35(1):e19-27. PubMed ID: 26398741
[TBL] [Abstract][Full Text] [Related]
2. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
[TBL] [Abstract][Full Text] [Related]
4. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
[TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
[TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
8. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
[TBL] [Abstract][Full Text] [Related]
10. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM
Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
[TBL] [Abstract][Full Text] [Related]
17. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
Halperin SA; Diaz-Mitoma F; Dull P; Anemona A; Ceddia F
Eur J Clin Microbiol Infect Dis; 2010 Mar; 29(3):259-67. PubMed ID: 20033465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
